Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Shares Sold by Millennium Management LLC

Millennium Management LLC lessened its holdings in shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Free Report) by 55.0% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 596,289 shares of the company's stock after selling 727,484 shares during the period. Millennium Management LLC owned about 1.34% of Werewolf Therapeutics worth $883,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Deutsche Bank AG boosted its position in shares of Werewolf Therapeutics by 450.7% during the fourth quarter. Deutsche Bank AG now owns 101,626 shares of the company's stock valued at $150,000 after purchasing an additional 83,172 shares in the last quarter. Levin Capital Strategies L.P. bought a new position in shares of Werewolf Therapeutics during the 4th quarter valued at $74,000. JPMorgan Chase & Co. boosted its position in Werewolf Therapeutics by 372.4% in the fourth quarter. JPMorgan Chase & Co. now owns 62,928 shares of the company's stock worth $93,000 after purchasing an additional 49,608 shares during the last quarter. Jane Street Group LLC increased its holdings in Werewolf Therapeutics by 261.2% during the fourth quarter. Jane Street Group LLC now owns 54,713 shares of the company's stock valued at $81,000 after buying an additional 39,564 shares during the last quarter. Finally, Bridgeway Capital Management LLC raised its holdings in Werewolf Therapeutics by 24.4% in the 4th quarter. Bridgeway Capital Management LLC now owns 109,586 shares of the company's stock worth $162,000 after purchasing an additional 21,500 shares during the period. Institutional investors own 64.84% of the company's stock.

Insider Activity

In other news, Director Ra Capital Management, L.P. purchased 162,539 shares of the business's stock in a transaction on Wednesday, May 14th. The shares were acquired at an average cost of $0.98 per share, with a total value of $159,288.22. Following the completion of the acquisition, the director now owns 6,237,482 shares of the company's stock, valued at $6,112,732.36. This trade represents a 2.68% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 23.60% of the company's stock.

Werewolf Therapeutics Trading Down 0.7%

NASDAQ:HOWL traded down $0.01 during mid-day trading on Monday, hitting $1.41. 467,615 shares of the stock traded hands, compared to its average volume of 437,656. The company has a quick ratio of 10.10, a current ratio of 10.10 and a debt-to-equity ratio of 0.29. The firm's 50 day moving average is $0.96 and its two-hundred day moving average is $1.27. Werewolf Therapeutics, Inc. has a 52 week low of $0.60 and a 52 week high of $4.18. The stock has a market capitalization of $63.27 million, a price-to-earnings ratio of -0.92 and a beta of 0.66.

Werewolf Therapeutics (NASDAQ:HOWL - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.04. Werewolf Therapeutics had a negative net margin of 578.80% and a negative return on equity of 58.83%. On average, equities research analysts predict that Werewolf Therapeutics, Inc. will post -1.56 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. HC Wainwright restated a "buy" rating and set a $15.00 price objective on shares of Werewolf Therapeutics in a research report on Wednesday, March 12th. Wedbush reduced their price target on shares of Werewolf Therapeutics from $8.00 to $6.00 and set an "outperform" rating on the stock in a research report on Friday, May 9th.

Werewolf Therapeutics Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.